Five-year mortality in patients with diabetic foot ulcer during 2009–2010 was lower than expected

Autor: Amadou, C., Carlier, A., Amouyal, C., Bourron, O., Aubert, C., Couture, T., Fourniols, E., Ha Van, G., Rouanet, S., Hartemann, A. ^*

Publikováno v: In Diabetes & Metabolism June 2020 46(3):230-235

Lower-extremity arterial revascularization: Is there any evidence for diabetic foot ulcer-healing?

Autor: Vouillarmet, J., Bourron, O., Gaudric, J., Lermusiaux, P., Millon, A., Hartemann, A.

Publikováno v: In Diabetes and Metabolism February 2016 42(1):4-15

Pie diabético

Autor: Ha Van, G., Amouyal, C., Perrier, A., Haddad, J., Bensimon, Y., Bourron, O., Hartemann, A.

Publikováno v: EMC - Cosmetologia Medica e Medicina degli Inestetismi Cutanei; March 2024, Vol. 21 Issue: 1 p1-21, 21p

Interleukin-2 and type 1 diabetes: New therapeutic perspectives

Autor: Hartemann, A., Bourron, O.

Publikováno v: In Diabetes and Metabolism November 2012 38(5):387-391

Combinatorial, additive and dose-dependent drug-microbiome associations

Autor: Forslund, SK, Chakaroun, R, Zimmermann-Kogadeeva, M, Markó, L, Aron-Wisnewsky, J, Nielsen, T, Moitinho-Silva, L, Schmidt, TSB, Falony, G, Vieira-Silva, S, Adriouch, S, Alves, RJ, Assmann, K, Bastard, J-P, Birkner, T, Caesar, R, Chilloux, J, Coelho, LP, Fezeu, L, Galleron, N, Helft, G, Isnard, R, Ji, B, Kuhn, M, Le Chatelier, E, Myridakis, A, Olsson, L, Pons, N, Prifti, E, Quinquis, B, Roume, H, Salem, J-E, Sokolovska, N, Tremaroli, V, Valles-Colomer, M, Lewinter, C, Søndertoft, NB, Pedersen, HK, Hansen, TH, Amouyal, C, Andersson Galijatovic, EA, Andreelli, F, Barthelemy, O, Batisse, J-P, Belda, E, Berland, M, Bittar, R, Blottière, H, Bosquet, F, Boubrit, R, Bourron, O, Camus, M, Cassuto, D, Ciangura, C, Collet, J-P, Dao, M-C, Djebbar, M, Doré, A, Engelbrechtsen, L, Fellahi, S, Fromentin, S, Galan, P, Gauguier, D, Giral, P, Hartemann, A, Hartmann, B, Holst, JJ, Hornbak, M, Hoyles, L, Hulot, J-S, Jaqueminet, S, Jørgensen, NR, Julienne, H, Justesen, J, Kammer, J, Krarup, N, Kerneis, M, Khemis, J, Kozlowski, R, Lejard, V, Levenez, F, Lucas-Martini, L, Massey, R, Martinez-Gili, L, Maziers, N, Medina-Stamminger, J, Montalescot, G, Moute, S, Neves, AL, Olanipekun, M, Le Pavin, LP, Poitou, C, Pousset, F, Pouzoulet, L, Rodriguez-Martinez, A, Rouault, C, Silvain, J, Svendstrup, M, Swartz, T, Vanduyvenboden, T, Vatier, C, Walther, S, Gøtze, JP, Køber, L, Vestergaard, H, Hansen, T, Zucker, J-D, Hercberg, S, Oppert, J-M, Letunic, I, Nielsen, J, Bäckhed, F, Ehrlich, SD, Dumas, M-E, Raes, J, Pedersen, O, Clément, K, Stumvoll, M, Bork, P, The MetaCardis Consortium (Hoyles, L.)

Publikováno v: Nature
Nature, 2021, 600 (7889), pp.500-505. ⟨10.1038/s41586-021-04177-9⟩

During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1-5. Here, through integrated mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d63d45a4e7d6e8c270f49c7d2bf0ce1
http://edoc.mdc-berlin.de/21160/1/21160oa.pdf